Sphera Funds Management LTD. acquired a new position in Erytech Pharma SA (NASDAQ:ERYP) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 120,000 shares of the company’s stock, valued at approximately $1,046,000. Sphera Funds Management LTD. owned approximately 0.67% of Erytech Pharma at the end of the most recent reporting period.
A number of analysts have recently issued reports on the stock. Cowen reissued a “buy” rating on shares of Erytech Pharma in a research note on Sunday, November 11th. Zacks Investment Research cut shares of Erytech Pharma from a “buy” rating to a “hold” rating in a research note on Thursday, September 13th.
ERYP opened at $7.00 on Friday. The firm has a market cap of $132.54 million and a P/E ratio of -2.10. Erytech Pharma SA has a fifty-two week low of $6.57 and a fifty-two week high of $23.46.
TRADEMARK VIOLATION NOTICE: This story was first published by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another site, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark laws. The original version of this story can be read at https://www.americanbankingnews.com/2018/12/08/sphera-funds-management-ltd-acquires-new-position-in-erytech-pharma-sa-eryp.html.
Erytech Pharma Profile
ERYTECH Pharma SA, a biopharmaceutical company, develops therapies for severe forms of cancer and orphan diseases. It is developing a pipeline of product candidates targeting solid and liquid tumors for patients with high unmet medical needs. The company's lead product candidate is eryaspase, which is used for the treatment of severe solid tumors, including pancreatic cancer and in acute lymphoblastic leukemia.
Recommended Story: Insider Trading
Receive News & Ratings for Erytech Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Erytech Pharma and related companies with MarketBeat.com's FREE daily email newsletter.